XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Note 9 - Share-based Compensation
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

9. Share-based Compensation

 

Our Third Amended and Restated 2006 Stock Option and Incentive Plan allows for granting of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, performance-based restricted stock units, unrestricted stock awards, and deferred stock awards to our officers, employees, directors and consultants. The components of share-based compensation expense were as follows:

 

   

Three months ended

   

Nine months ended

 
   

September 30,

   

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
   

(in thousands)

   

(in thousands)

 

Stock option awards

  $ 676     $ 614     $ 2,009     $ 1,840  

Restricted stock units

    481       432       1,443       1,231  

Performance-based restricted stock units

    156       140       463       418  
                                 

Total share-based compensation

  $ 1,313     $ 1,186     $ 3,915     $ 3,489  

 

Stock-based compensation is included in our statements of operations as follows:

 

   

Three months ended

   

Nine months ended

 
   

September 30,

   

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
   

(in thousands)

   

(in thousands)

 

Cost of sales

  $ 168     $ 142     $ 504     $ 415  

Sales and marketing

    248       205       712       607  

General and administrative

    765       720       2,310       2,127  

Research and development

    132       119       389       340  
                                 

Total stock-based compensation

  $ 1,313     $ 1,186     $ 3,915     $ 3,489  

 

During the nine months ended September 30, 2023 and 2022, we granted options for the purchase of 1,660 and 2,052 shares of our common stock, we granted restricted stock units of 944 and 728, and granted performance-based restricted stock units of 310 and 250, respectively. We issued approximately 180,000 and 81,000 shares of common stock following the exercise or vesting of underlying stock options or restricted stock units during the nine months ended September 30, 2023 and 2022, respectively.